Human factors and usability engineering in the development of SMT-101 for the treatment of pulmonary arterial hypertension. (3rd April 2018)

• Record Type: Journal Article
• Authors: Noymer, Peter; Shaked, Assaf; Newell, Kay
• Is Part Of: Expert opinion on drug delivery. Volume 15:Number 4(2018)
• Page Start: 325
• Page End: 333
• Publication Date: 2018-04-03
• Subjects: Human factors -- parenteral -- pulmonary arterial hypertension -- SMT-101 -- treprostinil -- wearable infusion pump; Drug delivery devices -- Periodicals; Drug delivery systems -- Periodicals; 615.605
• DOI: 10.1080/17425247.2018.1425390
• Languages: English
• ISSNs: 1742-5247

Abstract

ABSTRACT: Background: SMT-101, a novel, proprietary, water-resistant wearable infusion pump prefilled with a preset dosage of treprostinil, was designed to address many of the administration-related shortcomings of existing parenteral therapy for pulmonary arterial hypertension (PAH). The objective of the human factors (HF) program was to demonstrate that the SMT-101 system is safe and effective when used by patients with PAH, their caregivers, or healthcare providers. Methods: The HF program for SMT-101 consisted of 8 studies (148 participants): an ethnographic study, an online survey of patients with PAH, 4 formative studies, a study of the instructions for use (IFU), and a summative study for validation. The pump and IFU were iteratively modified using observational data and participant feedback to inform subsequent improvements throughout the HF program to optimize safe use of SMT-101 before the final study. Results: The results of the summative study demonstrated that the design of the SMT-101 wearable, pre-filled infusion pump and IFU are safe and effective for use. Conclusions: In accordance with regulatory guidelines, the usability and HF aspects of SMT-101 were developed and refined through a rigorous HF program in patients with PAH and healthcare providers, which culminated in a summative study that validated the usability and use-safety of SMT-101.